HomePress-release

Redding, California - July 2, 2024

Europe Pharmaceutical Contract Development and Manufacturing Market to be worth $68.12 Billion by 2032

Europe Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Forecast to 2032

Meticulous Research^®, a leading global market research company, published a research report titled, 'Europe Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Forecast to 2032.’

According to this latest publication from Meticulous Research^®, the europe pharmaceutical contract development and manufacturing market is expected to reach $68.12 billion by 2032 at a CAGR of 7.4% from 2025 to 2032. The growth of the Europe pharmaceutical contract development and manufacturing market is attributed to the rising incidence & prevalence of chronic illness, rising awareness of overall health and treatment availability, growing geriatric population in the region, rising pharmaceutical R&D expenditure, low-cost manufacturing advantages, increasing government funding for drug development and research, improving healthcare infrastructure, and growing healthcare spending.

The lack of skilled professionals is challenging the growth of this market. High demand for personalized medicine, cell therapies, and gene therapies, and growth in high potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) market in European countries are providing opportunities for market growth.

Key Players

The key players operating in the Europe pharmaceutical contract development and manufacturing market are AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn Ag & Co. KG. (Germany), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), Fabbrica Italiana Sintetici S.p.A. (Italy), and Corden Pharma GmbH (Germany).

Europe Pharmaceutical Contract Development and Manufacturing Market: Future Outlook

The Europe pharmaceutical contract development and manufacturing market is segmented by Type (Pharmaceutical Manufacturing Services {Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services [Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, and Other Formulations]}, Drug Development Services, and Biologics Manufacturing Services{Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services}), End User (Large Pharmaceutical Companies, Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical Companies), and Countries. The study also evaluates industry competitors and analyzes their market share at the country level.

Among all types studied in this report, in 2025, the pharmaceutical manufacturing services segment is expected to account for the largest share of the Europe pharmaceutical contract development and manufacturing market. The pharmaceutical manufacturing services segment is further segmented into active pharmaceutical ingredient (API) manufacturing services and finished dosage forms (FDF) manufacturing services. The largest share of this segment is attributed to the need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.

Among all end users studied in this report, the generic pharmaceutical companies segment is expected to register the highest CAGR over the forecast period. The growth of this end-user segment is driven by the increasing competition in the generic market leading to pricing pressure and the growing inclination of these companies toward the use of cutting-edge technologies offered by contract development and manufacturing firms.

Geographic Review

This research report comprehensively analyzes major countries Germany, the U.K., France, Italy, Spain, Switzerland, Netherlands, Denmark, and the Rest of Europe. In 2025, Germany is expected to account for the largest share of the Europe pharmaceutical contract development and manufacturing market. Germany is the largest exporter of medicinal products and ranks among the top pharmaceutical producers worldwide. Considering the global need for personalized medicine, Germany has also evolved into one of the main suppliers of novel biopharmaceuticals. This is expected to drive the country's demand for pharmaceutical contract development and manufacturing services.

CDMOs are inaugurating newer facilities to meet the growing demand, which is the new trend seen in the CDMOs market in Germany. For instance, In July 2021, Richter-Helm Biologics GmbH & Co. KG (Germany) inaugurated a new manufacturing facility in Bovenau, Germany, to triple its biopharmaceutical production capacity.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5592

Key questions answered in the report-

Which are the high-growth market segments in terms of type, end user, and country?
What was the historical market for pharmaceutical contract development and manufacturing services in Europe?
What are the market forecasts and estimates for the period 2025–2032?
What are the major drivers, restraints, challenges, and opportunities in the Europe pharmaceutical contract development and manufacturing market?
Who are the major players in the Europe pharmaceutical contract development and manufacturing market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & WastewaterTechnologies

Miscellaneous / Others

Redding, California - July 2, 2024

Europe Pharmaceutical Contract Development and Manufacturing Market to be worth $68.12 Billion by 2032

Europe Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Forecast to 2032

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies